Parenteral anticoagulation in ambulatory patients with cancer

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 9, 2017, Pages

  Akl, Elie A ^a   Kahale, Lara A ^a   Hakoum, Maram B ^a   Matar, Charbel F ^a   Sperati, Francesca ^b   Barba, Maddalena ^b   Yosuico, Victor E D ^c   Terrenato, Irene ^b   Synnot, Anneliese ^d,e   Schünemann, Holger ^f  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Buffalo Medical Group   (United States)

^d MONASH UNIVERSITY   (Australia)

^e LA TROBE UNIVERSITY   (Australia)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PLACEBO; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AMBULATORY CARE; ANTICOAGULANT THERAPY; BLEEDING; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; CAUSE OF DEATH; CHEMICALLY INDUCED; META ANALYSIS; NEOPLASM; QUALITY OF LIFE; SURVIVAL ANALYSIS; TIME FACTOR;

ANTICOAGULANTS; CAUSE OF DEATH; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TIME FACTORS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 85029090090     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006652.pub5     Document Type: Review

References (252)

1. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology 2009;10(10):943-9. 2702911
2. Agnelli G, Gussoni G, Bianchini C, Verso M, Tonato M. A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Blood 2008;112:6. 2702912
3. Agnelli G, Tonato M. Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study. Support Care Cancer 2009;17:857-1039. 6668978
4. Barni S, Labianca R, Agnelli G, Bonizzoni E, Mandalà M, Verso M, et al. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer. Support Care Cancer 2011;19(Suppl 2):S206, 415. 6668979
5. Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine 2011;9(179):1-7. 6668980
6. Agnelli G, George D, Fisher WD, Kakkar AK, Lassen MR, Mismetti P, et al. Ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: consistent beneficial effect across cancer stage and location subgroups. European Journal of Cancer 2011;47:S222. 2702914
7. Agnelli G, George DJ, Fisher W, Kakkar AK, Lassen MR, Mismetti P, et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Annual Meeting. Journal of Clinical Oncology 2011;29:LBA9014. 2702915
8. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine 2012;366(7):601-9. 2702916
9. George D, Agnelli G, Fisher W, Kakkar A, Lassen MR, Mismetti P, et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. 53rd Annual Meeting of the American Society of Hematology. Blood 2011;118(21):96. 2702917
10. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV): low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). Proceedings of the American Society of Clinical Oncology. 2001; Vol. 20:1280. 2702919
11. Altinbas M, Coskun HS, Ozkan M, Eser B, Unal A, Cetin M, et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis 2004;2:1266-71. 2702920
12. Altinbas M, Ozkan M, Coskun HS, Er O, Eser B, Unal A, et al. Efficiency of cyclophosphamide, epirubicin, vincristine (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): preliminary results. Annals of Oncology 2000;11:117. 2702921
13. Freund M, Kakkar AK, Haas S, Heilmann L, von Tempelhoff GF, Brom J, et al. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. Blood 2003;102(11):210A. 2702923
14. Gatzemeier U, Freund M, Haas S, Kakkar A, Zatloukai P, Kelbel C, et al. Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2). Lung Cancer 2005;49:S56. 2702924
15. Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, et al. Low- molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer-TOPIC 1. Clinical and Applied Thrombosis/Hemostasis 2012;18(2):159-65. 2702925
16. Haas SK, Kakkar AK, Kemkes-Matthes B, Freund M, Gatzemeier U, Heilmann L, et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. Journal of Thrombosis & Haemostasis 2005;3(1):OR059. 2702926
17. Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer- TOPIC 2. Clinical and Applied Thrombosis/Hemostasis 2012;18(2):159-65. 2702928
18. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Journal of Clinical Oncology 2004;22(10):1944-8. 2702930
19. Khorana AA, Francis CW, Kuderer N, Carrier M, Ortel TL, Wu, T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, http://dx.doi.org/10.1016/j.thromres.2017.01.009 2017. [DOI: http://dx.doi.org/10.1016/j.thromres.2017.01.009]6668982
20. Khorana AA, Francis CW, Kuderer N, Carrier M, Ortel TL, Wun T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Blood 2015;126(23):427. 6668983
21. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology 2005;23(10):2130-5. 2702932
22. Klerk CPW, Smorenburg S, Otten HM, Richel D, Tienhoven G, Lensing A, et al. Low-molecular-weight heparin and the survival of patients with advanced malignancy [abstract]. Journal of Clinical Oncology: ASCO annual meeting proceedings 2004;22:729. 6668984
23. Klerk CPW, Smorenburg SM, Otten JMMB, Buller HR. Malignancy and low molecular weight-heparin therapy: the MALT trial. Pathophysiology of Haemostasis and Thrombosis 2003;33(Suppl 1):75. 2702933
24. Klerk CPW, Smorenburg SM, Otten JMMB, Buller HR. Malignancy and low-molecular weight-heparin therapy: the MALT trial. Abstracts from XIX International ISTH Congress. Journal of Thrombosis & Haemostasis 2003;1(Suppl 1):OC195. 2702934
25. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994;74(1):38-45. 2702936
26. Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thrombosis Research 2013;132(6):666-70. 2702938
27. Lecumberri R, Massuti B, López Vivanco G, Font A, González Billalabeitia E, Rocha E, on behalf of the ABEL Investigators. Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. 5th ICTHIC Abstracts: Oral Communications/Thrombosis Research. 2010; Vol. 125:S161-5. 2702939
28. Massuti B, Lecumberri R, Lopez Vivanco GM, Font A, Gonzalez-Billalabeitia E, Marti-Ciriquian JL, et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)--Final results. ASCO Annual Meeting Proceedings 2012;30(15):7095. 6668985
29. Massuti B, Lopez-Vivanco G, Font A, Lecumberri R, Gonzalez Billalabeitia E, Marti, et al. Multicenter randomized phase ii trial of adding Bemiparin to chemo-radio therapy in small cell Lung cancer with limited disease. Annals of Oncology 2010;21:159. 6668986
30. Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS. FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC cancer 2009;9(1):1. 6668988
31. Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology 2016;34(5):488-94. 6668989
32. Macbeth F, Noble S, Griffiths G, Chowdhury R, Rolfe C, Hood K, et al. Preliminary results from the fragmatic trial: a randomised phase iii clinical trial investigating the effect of fragmin (r) added to standard therapy in patients with lung cancer. Journal Of Thoracic Oncology 2013;8:S243. 6668990
33. Noble S, Robbins A, Alikhan R, Hood K, Macbeth F. Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis 2015;13:143. 6668991
34. Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer 2012;48(9):1283-92. 2702941
35. Maraveyas A, Waters J, Roy R, Propper D, Fyfe D, Lofts F, et al. OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Thrombosis Research 2010;125:S161. 6668992
36. Maraveyas AJ, Waters R, Roy D, Propper D, Fyfe F, Lofts E, et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer 2009;Supplements 7(2):362. 6668993
37. Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, Hahnfeld S, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. Onkologie - DGHO meeting. October 2009; Vol. 580:Abstract. 2702943
38. Pelzer U, Hilbig A, Stieler J, Roll L, Riess H, Dorken B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Onkologie 2005;28(Suppl 3):54 (Abstract 151). 2702944
39. Pelzer U, Hilbig A, Stieler J, Roll L, Stauch M, Opitz B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004). ASCO Annual Meeting Proceedings 2006;24(18):4110. 6668994
40. Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer 2014;14:204. 6668995
41. Pelzer U, Oettle H, Stauch M, Opitz B, Stieler J, Scholten T, Riess T. Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy. XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 July 6-12; Geneva. 2007:P-T-488. 2702945
42. Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. Journal of Clinical Oncology 2015;33(18):2028-34. 6668996
43. Riess H, Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. ASCO Annual Meeting Proceedings 2009;27(18S):LBA4506. 6668997
44. Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 2008;8:361. 2702946
45. Riess H, Pelzer U, Opitz B, Stauch M, Reitzig P, Hahnfeld S, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. Journal of Clinical Oncology Conference 2010;28(15 suppl):4033. 6668998
46. Riess HB, Pelzer U, Opitz B, Hilbig A, Strauch M, Hahnfeld S, et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis 2009;7(Suppl. 2):1-1204. 6668999
47. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Hemostasis 2010;8(9):1959-65. 2702948
48. Perry JR, Rogers L, Laperriere N, Julian J, Geerts W, Agnelli G, et al. for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. Journal of Clinical Oncology 2007;25:77s (Abstract 2011). 2702949
49. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Dakhil SR, et al. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: a North Central Cancer Treatment Group study. Journal of Clinical Oncology 2005;23(16):775S. 2702951
50. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, et al. Low-molecular-weight-heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings 2006;81(6):758-67. 2702952
51. Buller HR, Prins MH. Late breaking clinical trial: the effect of the low molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the inpact investigators). Journal of Thrombosis and Hemostasis 2009;7:1203. 6669000
52. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology 2011;29:2071-6. 2702954
53. Weber C, Merminod T, Herrmann FR, Zulian GB. Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer 2008;16(7):847-52. 2702956
54. Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). British Jjournal of Haematology 2013;160(4):530-7. 6669002
55. Zwicker, J, H. A. Liebman, K. A. Bauer, T. Caughey, R. Rosovsky, S. Mantha, C. M. Kessler, et al. A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the microtec study). Journal Of Thrombosis And Haemostasis 2013;11:6. 6669003
56. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. New England Jjournal of Medicine 1998;339(2):80-5. 6669005
57. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. British Journal of Surgery 2005;92(10):1212-20. 6669007
58. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Pak R, et al. Apixaban for the treatment of venous thromboembolism in cancer patients: Data from the amplify trial. Canadian Journal of Cardiology 2014;30:S278. 6669009
59. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis 2015;13(12):2187191. 6669010
60. Alifano M, Maggiore O, Benedetti G, Trisolini R. Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer? An urgent call for research. Chest 2004;126:601-7. 2702958
61. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation & Fibrinolysis 2003;14(4):341-6. 6669012
62. Samama, M.M, Cohen, A.T, Darmon, J.Y, Desjardins, L, Eldor, A, Janbon, C, Leizorovicz, A, Nguyen, H, Olsson, C.G, Turpie, A.G, Weisslinger. N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine 1999;341(11):pp.793-800. 6669013
63. Arbit E, Alifano M, Maggiore O, Benedetti G, Trisolini R. Low-molecular-weight heparin and outcomes. Chest 2005;128(1):471-2. 2702960
64. Auer R, Scheer A, Wells PS, Boushey R, Asmis T, Jonker D, et al. The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial. Blood Coagulation & Fibrinolysis 2011;22(8):760-2. 6669015
65. Barberi-Heyob M, Merlin JL, Vigneron M, Conroy T. Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions. Anti-Cancer Drugs 1995;6(1):163-4. 2702962
66. Barkagan ZS. The results of the use of low molecular weight heparin (LMWH) for prevention and treatment of thrombosis in cancer patients. Thrombosis and Haemostasis 1997;-:772. 2702964
67. Bigg SW, Catalona WJ. Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial. Urology 1992;39(4):309-13. 6669017
68. Bitsch M, Hermann GG, Andersen JP, Steven K. Low dose intravesical heparin as prophylaxis against recurrent noninvasive (stage Ta) bladder cancer. Journal of Urology 1990;144(3):635-6. 2702966
69. Blaszczyk M, Ursyn-Niemcewicz W, Pawlak F. Heparin precipitable fraction (HPF) in malignant tumors of the respiratory tract. Gruzlica i Choroby Pluc 1970;38(4):321-8. 2702968
70. Buckman RA, Wong NS, Clemons M, Verma S, Trudeau ME, Roche K, et al. Phase I-II study of DaICM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC). Journal of Clinical Oncology 2005;23(16):52S. 2702970
71. Cahan, M.A, Hanna, D.J, Wiley, L.A, Cox, D.K, Killewich. L.A. External pneumatic compression and fibrinolysis in abdominal surgery. Journal of vascular surgery 2000;32(3):537-543. 6669019
72. Cavallo F, Di Raimondo F, Harda I, Lupo B, Romano A, Catalano L, et al. A phase III study of enoxaparin vs aspirin as thromboprophylaxis for newly diagnosed myeloma patients treated with lenalidomide-based regimen. American Society of Hematology Annual Meeting 1092. 2010. 2702972
73. Chojnowski K, Trelinski J, Wawrzyniak E, Robak T. The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy - report of prospective randomized study. Leukemia and Lymphoma 2002;43(5):1021-8. 2702974
74. Cicco MD, Matovic M, Balestreri L, Steffan A, Pacenzia R, Malafronte M, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. Annals of Oncology 2009;20:1936-42. 2702976
75. Clarke-Pearson, Daniel L, Ingrid S. Synan, Richard Dodge, John T. Soper, Andrew Berchuck, R. Edward Coleman. "A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery.". American journal of obstetrics and gynecology 1993;168(4):1146-1154. 6669021
76. Cohen AT, Wagner MB, Mohamed MS. Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis. The American journal of surgery 1997;174(1):1-5. 6669023
77. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Das SK, Maher KT, Sanderson RM, Kakkar S, Cooper DJ. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Lancet 1993 Jan 30;341(8840):259-65. 6669024
78. Cohen, Alexander T, Bruce L. Davidson, Alexander S. Gallus, Michael R. Lassen, Martin H. Prins, Witold Tomkowski, Alexander GG Turpie, Jan FM Egberts, Anthonie WA Lensing. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2003;332(7537):325-329. 6669026
79. Cohen, Alexander T, Bruce L. Davidson, Alexander S. Gallus, Michael R. Lassen, Martin H. Prins, Witold Tomkowski, Alexander GG Turpie, Jan FM Egberts, Anthonie WA Lensing. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332(7537):325-329. 6669028
80. Cohen, A.T, Davidson, B.L, Gallus, A.S, Lassen, M.R, Prins, M.H, Tomkowski, W, Turpie, A.G, Egberts, J.F, Lensing. A.W. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332(7537):325-329. 6669030
81. Cohen, A.T, Turpie, A.G, Leizorovicz, A, Olsson, C.G, Vaitkus, P.T, Goldhaber. S.Z. Thromboprophylaxis with dalteparin in medical patients: which patients benefit?. Vascular Medicine 2007;12(2):123-127. 6669031
82. Leizorovicz, A, Cohen, A.T, Turpie, A.G, Olsson, C.G, Vaitkus, P.T, Goldhaber, S.Z. and PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110(7):874-879. 6669032
83. Anderson, D, et al. A randomized double-blind placebo controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Journal of thrombosis and haemostasis 2003;JTH 1:Abstract no: P198. 6669034
84. Couban, S, Goodyear, M, Burnell, M, Dolan, S, Wasi, P, Barnes, D, MacLeod, D, Burton, E, Andreou, P, Anderson. D.R. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. Journal of Clinical Oncology 2005;23(18):4063-4069. 6669035
85. Couban, S, M. Goodyear, M. Burnell, S. Dolan, P. Wasi, D. Macleod, E. Burton, P. Andreou, D. Anderson. A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Blood, American Society of Hematology 44th Annual Meeting, Abstract No. 2769 2002;100(11):703A. 6669036
86. Craven R. Heparin and cancer revisited. Trends in Pharmacological Sciences 2001;22(5):1. 2702978
87. Crossno RJ. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Journal of Pain and Palliative Care Pharmacotherapy 2009;23(1):65-6. 2702980
88. DeMir M, Hoppensteadt DA, Cunanan J, Iqbal O, Fareed J. Increased levels of inflammatory mediators in lung cancer and their modulation by oral anticoagulant treatment. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2006;108(11):892. 2702982
89. Demir M, Ciftci A, Hoppensteadt D, Altiay G, Tobu M, Iqbal O, et al. Protein chip array profiling and markers of inflammation and thrombin generation in plasma samples from lung cancer patients and their modulation by chemotherapy with or without warfarin anticoagulation. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. 2007. 2702984
90. Dickinson LD, Miller LD, Patel CP, Gupta SK, et al. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998;43(5):1074-81. 6669038
91. Di Nisio M, Buller HR, Porreca E. Do low-molecular-weight heparins improve the survival of cancer patients?. Nature Clinical Practice Oncology 2005;2(12):612-3. 2702986
92. Edlis HE, Goudsmit A, Brindley C, Niemetz J. Trial of heparin and cyclophosphamide (NSC-26271) in the treatment of lung cancer. Cancer Treatment Report 1976;60(5):575-8. 2702988
93. Eichinger S, Traby L, Kaider A, Quehenberger P, Kyrle PA. Prevention of venous thrombosis in cancer patients: a randomized, double-blind study comparing two different dosages of low-molecular weight heparin. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. 2008. 2702990
94. Elias EG, Brugarol A. Role of heparin in chemotherapy of solid tumors - preliminary clinical trial in carcinoma of lung. Cancer Chemotherapy Reports Part 1 1972;56(6):783-5. 2702992
95. Elias EG. Heparin as an adjuvant to chemotherapy In lung carcinoma. Proceedings of the American Association for Cancer Research. 1973; Vol. 14:26. 2702994
96. Elias EG, Sepulveda F, Mink IB. Increasing the efficiency of cancer chemotherapy with heparin: "clinical study". Journal of Surgical Oncology 1973;5(2):189-93. 2702996
97. Elias EG. Heparin therapy combined with chemotherapy in metastatic cancer. Cancer Bulletin 1973;25(6):116-9. 2702998
98. Elias EG. Heparin anticoagulation as adjuvant to chemotherapy in carcinoma of the lung. Journal of Medicine 1974;5(1):114-32. 2703000
99. Elias EG, Shukla SK, Mink IB. Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer 1975;36(1):129-36. 2703002
100. Elit LM, Lee AY, Parpia S, Swystun LL, Liaw PC, Hoskins P, et al. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis Research 2012;130:894-900. 2703004
101. Fielding LP, Hittinger R, Grace RH, Fry JS. Randomized controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340(8818):502-6. 2703006
102. Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest Journal 2002;122(6):1933-7. 6669040
103. Graf B, Graf AH, Traun H, Forstner K, Rettenbacher L, Sailer S, et al. Prophylaxis of thromboembolism in radiotherapy for gynecologic malignancies: low molecular weight (LMW) heparin (fragmin (R)) vs coumarin (sintrom(R)). Haemostasis 1994;24(Suppl 1):315 (Abstract 6). 2703008
104. Graf AH, Graf B, Traun H, Staudach A. Risk and prevention of thromboembolism complications in gynecologic malignancies. Gynakologisch-Geburtshilfliche Rundschau 1996;36(1):37-9. 2703010
105. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992;339(8807):1476. 2703012
106. Guimbretiere J, Raffi F, Dabouis G. Heparin therapy in hypercoagulable state of lung cancer patients. Haemostasis 1982;12(1-2):139. 2703014
107. Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser C, et al. CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis 2011;105(6):981-8. 6669042
108. Haas S, Schellong SM, Tebbe U, Gerlach HE, Bauersachs R, Abletshauser C, et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolicevents in the patients with cancer. Hämostaseologie 2011;31(1):A10. 6669043
109. Haas S, Schellong SM, Tebbe U, Gerlach HE, Bauersachs R, Melzer N, et alAbletshauser C, et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer-a subgroup analysis of CERTIFY. BMC Cancer 2011;11(1):1. 6669044
110. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Pathophysiology of Haemostasis and Thrombosis 1996;26(3):127-39. 6669046
111. Harenberg J, Roebruck P, Stehle G, Habscheid W, Biegholdt M, Heene DL. Heparin Study in Internal Medicine (HESIM): design and preliminary results. Thrombosis Research 1992;68(1):33-43. 6669047
112. Hata K, Kimura T, Tsuzuki S, Ishii G, Kido M, Yamamoto T, et al. Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: A prospective randomized clinical trial [Hata K, Kimura T, Tsuzuki S, Ishii G, Kido M, Yamamoto T, et al]. International Journal of Urology 2016;23(11):923-8. 6669049
113. Hoppensteadt D, Khan H, Thethi I, Demir M, Adiguzel C, Rahman S, et al. Inflammatory and thrombotic mediators in small cell lung carcinoma: potential role in thromboembolic complications. American Society of Hematology, Annual Meetings and Exposition 2294. 2011. 2703016
114. Kakkar VV, Balibrea J, Martinez-Gonzalez J, Prandoni P. Late breaking clinical trial: a randomised double blind trial to evaluate the efficacy and safety of prolonging the thromboprophylaxis with bemiparin in patients undergoing cancer abdominal or pelvic surgery (theCANBESURE study). International Society on Thrombosis and Haemostasis 2009;7(suppl. 2):1202, LB-MO-002. 6669051
115. Kakkar, VV, Balibrea JL, Martinez-Gonzalez J, Prandoni P. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. Journal of Thrombosis and Haemostasis 2010;8(6):1223-9. 6669052
116. Kakkar AK, Agnelli G, Fisher W, George D, Lassen MR, Mismetti P, et al. and SAVE-ABDO Investigators. Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. Annals of Surgery 2014;259(6):1073-9. 6669054
117. Kakkar AK, Agnelli G, Fisher WD, George D, Mouret P, Lassen MR, et al. The ultra-low-molecular-weight heparin semuloparin for prevention of venous thromboembolism In patients undergoing major abdominal surgery. Blood 2010;116(21):188. 6669055
118. Kohanna FH, Sweeney J, Hussey S. Effect of perioperative low-dose heparin administration on the course of colon cancer. Surgery 1983;93(3):433-8. 2703022
119. Koppenhagen K, Adolf J, Matthes M, Tröster E, Roder JD, Hass S, et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thrombosis and Haemostasis 1992;67(6):627-30. 6669057
120. Larocca A, Cavallo F, Bringhen S, Raimondo FD, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012;119:933-9. 2703024
121. Lecumberri R, Paramo JA, Rocha E. Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies. Haematologica 2005;90(9):1258-66. 2703026
122. Bauersachs R. Catch-a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports 2011;3:13. 6669060
123. Bauersachs R, Lee AYY, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients-analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis 2015;13:76. 6669059
124. Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism-the CATCH study. Journal of Thrombosis and Haemostasis 2015;13:182-3. 6669061
125. Khorana AA, Bauersachs R, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study. Journal of Clinical Oncology Conference 2015;33(15 suppl 1):9621. 6669062
126. Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013;13(1):284. [NCT01130025]6669063
127. Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013;13:284. 6669064
128. Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology 2012;Suppl:TPS9149. 6669065
129. Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA: Journal of the American Medical Association 2015;314:677. 6669066
130. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. A randomized trial of long-term tinzaparin, a Low Molecular Weight Heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients-the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology 2014;124:21. 6669067
131. Lemoine NR. Antithrombotic therapy in cancer. Journal of Clinical Oncology 2005;23(10):2119-20. 2703028
132. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343(8902):886-9. 2703030
133. Levine MN, Lee AYY, Kakkar AK. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: is there any difference in cancer-related mortality? Reply. Journal of Clinical Oncology 2005;23(28):7250. 2703032
134. Levine M, Gu C, Liebman HA, Escalante P, Solymoss S, Deitchman D, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. Journal of Thrombosis and Haemostasis 2012;10:807-14. 2703034
135. Liebman H, Levine MN, Deitchman D, Julian J, Escalante CP, O'Brien MC, et al. Apixaban in patients with metastatic cancer: a randomized phase II feasibility study. International Society on Thrombosis and Haemostasis. 2009; Vol. 7 (Suppl 2):792. 2703036
136. Loprinzi C, Kugler J, Sloan J, Rooke T, Quella S, Novotny P, et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. New England Journal of Medicine 1999;340:346-50. 2703038
137. Loynes JT, Zacharski LR, Rigas JR. Regression of metastatic non-small cell lung cancer with low molecular weight heparin. Thrombosis and Haemostasis 2002;88(4):686. 2703040
138. Lykke J, Rasmussen HM, Nielsen HJ. Heparin as adjuvant in the treatment of colorectal cancer?. Ugeskrift for Laeger 2003;165(18):1866-7. 2703042
139. Mammen EF. Expanded role of low-molecular-weight heparins in hematologic and oncologic indications. Seminars in Thrombosis and Hemostasis 2004;30(Suppl 1):1-2. 2703044
140. Maraveyas A, Ettelaie C, Echrish H, Li C, Gardiner E, Greenman H, et al. Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. Blood Coagulation Fibrinolysis 2010;21:452-8. 2703046
141. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. American College of Obstetricians and Gynecologists 2001;98(6):989-95. 6669069
142. Mazilu L, Parepa IR, Suceveanu AI, Suceveanu A, Baz R, Catrinoiu D. Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research 2014;103(suppl 1):S39, P221. 6669071
143. Meyer G. Does low-molecular-weight heparin influence cancer-related mortality. Annals of Oncology 2007;18(3):609-10. 2703048
144. Mousa SA, Mohammed S. Anti-angiogenesis mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy beyond its anticoagulants. Blood 2001;98(11):181B. 2703050
145. Munstedt K, Kemkes-Matthes B, Matthes KJ, Vahrson H. The behavior of the activation parameters of plasma coagulation under HDR-afterloading therapy in patients with endometrial carcinoma (German). Strahlentherapie und Onkologie 1996;172(1):39-42. 2703052
146. Murakami M, Wiley LA, Cindrick-Pounds L, Hunter GC, Uchida T, Killewich LA. External pneumatic compression does not increase urokinase plasminogen activator after abdominal surgery. Journal of Vascular Surgery 2002;36(5):917-921. 6669073
147. Nagata C, Tanabe H, Takakura S, Narui C, Saito M, Yanaihara N, et al. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. Journal of Obstetrics and Gynaecology Research. 2015;41(9):1440-8. 6669075
148. Nash G. Heparin for colorectal cancer. Journal of the Royal Society of Medicine 2000;93(10):554. 2703054
149. Nishioka J, Goodin S. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. Journal of Oncology Pharmacy Practice 2007;13(2):85-97. 2703056
150. Nitti D, Wils J, Sahmoud T, Curran D, Couvreur ML, Lise M, et al. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer 1997;33(8):1209-15. 2703058
151. Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thrombosis Haemostasis 1996;75:233-8. 6669077
152. Cavo M, Palumbo A, Bringhen S, Di Raimondo F, Patriarca F, Rossi D, et al. Phase III Study of enoxaparin versus aspirin versus low-dose warfarin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated upfront with thalidomide-containing regimens. Haematologica 2010;95:391. 6669078
153. Cavo M, Palumbo A, Bringhen S, Falcone A, Musto P, Ciceri F, et al. A phase III study of enoxaparin versus low-dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide-containing regimens. Blood 2008;112(11):3017. 6669079
154. Cavo M, Palumbo A, Bringhen S, Falcone A, Musto P, Ciceri F, et al. A phase III study of enoxaparin versus low-dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide-containing regimens. Haematologica 2009;94:s4. 6669080
155. Magarotto V, Brioli A, Patriarca F, Rossi D, Petrucci MT, Nozzoli C, et al. Enoxaparin, aspirin, or warfarin for the thromboprophylaxis in newly diagnosed myeloma patients receiving thalidomide: a randomized controlled trial. XI Congress Of The Italian Society Of Experimental Hematology 2010;95:S1-S162. 6669081
156. Palumbo A, Cavo M, Bringhen S, Zaccaria A, Spadano A, Palmieri S, et al. Enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide-containing regimens: a randomized, controlled trial [Abstract No. 0910]. Haematologica 2008;93:362. 6669082
157. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. Journal of Clinical Oncology 2011;29:986-993. 6669083
158. Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology 2014;1(1):e37-e46. 6669085
159. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology 2016;3(8):e379-e387. 6669087
160. Retik AB, Arons MS, Ketcham AS, Mantel N. The effect of heparin on primary tumors and metastases. Journal of Surgical Research 1962;2:49-53. 2703062
161. Rohwedder JJ, Sagastume E. Heparin and polychemotherapy for treatment of lung cancer. Cancer Treatment Report 1977;61(7):1399-401. 2703064
162. Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. Thrombosis Research 2010;125(3):e65-70. 6669089
163. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, Investigators TI, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New England Journal of Medicine 2003;349(18):1713-21. 6669091
164. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine 2013;368(8):709-18. 6669093
165. Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis 2015;114(1):150-7. 6669095
166. Siragusa S. Low molecular weight heparins could be important in cancer. BMJ 1999;319(7213):851. 2703066
167. Song KY, Yoo HM, Kim EY, Kim JI, Yim HW, Jeon HM, et al. Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial. Annals of Surgical Oncology 2014;21(13):4232-8. 6669097
168. Spigel DR. Low-molecular-weight heparin improves survival in patients with cancer. Journal of Clinical Outcomes Management 2005;12(5):241-2. 2703068
169. Stanford CF. Anticoagulants in the treatment of small cell carcinoma of the bronchus. Thorax 1979;34:113-6. 2703070
170. Thethi I, Hoppensteadt D, Khan H, Demir M, Adiguzel C, Litinas E, et al. Procoagulant and inflammatory mediators in small cell lung carcinoma: Potential role in thromboembolic complications. Journal of Clinical Oncology 2011;29(Suppl):2553. 2703072
171. Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle P, et al. The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. Thrombosis and Haemostasis 2010;104:92-9. 2703074
172. Vadhan-Raj S, Zhou X, Varadhachary GR, Milind J, Fogelman D, Shroff R, et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): Risk factors predictive of VTE. Blood 2013;122(21):580. 6669098
173. Becattini C, Rondelli F, Vedovati MC, Camporese G, Giustozzi M, Boncompagni M, et al. Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. Haematologica 2015;100(1):e35-e38. 6669100
174. Becattini C, Rondelli, F, Vedovati MC, Camporese G, Giustozzi M, Boncompagni M, et al. Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. Haematologica 2014;99:doi:10.3324/haematol.2014.109843. 6669101
175. Becattini C, Vedovati MC, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. One week vs. four week heparin prophylaxis after laparoscopic surgery for colorectal cancer. The pro-laps pilot feasibility study. Journal of Thrombosis and Haemostasis 2013;11:11. 6669102
176. Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. A randomized study on 1 vs. 4 weeks prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Journal of Thrombosis and Haemostasis 2013;11:214. 6669103
177. Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Annals of Surgery 2014;259(4):665-9. 6669104
178. Agnelli G, Verso M, Bertoglio S, Ageno W, Bazzan M, Parise P, et al. A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter. Journal of Clinical Oncology. 2004; Vol. 22:734S. 6669106
179. Verso M, Agnelli G, Bertoglio S, Di Somma C, Paoletti F, Ageno W, et al. A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter. 2003 Journal of Thrombosis and Haemostasis;1(Suppl 1 Jul):Abstract: no P0825. 6669107
180. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. Journal of Clinical Oncology 2005;23(18):4057-62. 6669108
181. Verso M, Agnelli G, Kamphuisen PW, Ageno W, Bazzan M, Lazzaro A, et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Internal and Emergency Medicine 2008;3(2):117-22. 6669109
182. Hugo R, Hafter R, Hiller KF, Lochmuller H, Selbmann HK, Graeff H. Prevention of deep vein thrombosis in patients with gynaecologic cancer undergoing radiotherapy. A comparison of calcium-heparin and semi-synthetic heparin analogue [Thromboembolische Komplikationen waehrend der Strahlenbehandlung gynaekologischer karzinome]. Geburtshilfe und Frauenheilkunde 1981;41(3):179-83. 2703076
183. Ward B, Pradhan S. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery. Australian and New Zealand Journal of Obstetrics and Gynaecology 1998;38(1):91-2. 6669111
184. Wester JPJ, de Valk H, Nieuwenhuis HK, Banga JD. Risk factors for bleeding during treatment of acute venous thromboembolism. Thrombosis and Haemostasis 1996;76(5):682-8. 6669113
185. de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatmentof venous thromboembolism. A randomized controlled trial. Annals of Internal Medicine 1995;123(1):1-9. 6669114
186. Wojtukiewicz MZ, Kozlowski L, Ostrowska K, Dmitruk A, Zacharski LR. Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial. Thrombosis and Haemostasis 2003;89(2):405-7. 2703078
187. Zacharski LR. Heparin treatment of malignancy: the case for clinical trials in colon cancer. Thrombosis Research 2003;110(4):213-4. 2703080
188. Zheng H, Gao Y, Yan X, Gao M, Gao W. Prophylactic use of low molecular weight heparin in combination with graduated compression stockings in post-operative patients with gynecologic cancer. Zhonghua zhong liu za zhi [Chinese Journal of Oncology] 2014;36(1):39-42. 6669116
189. A randomized phase II open-label study to assess the efficacy & safety of gemcitabine + Abraxane® with or without ODSH (2-0, 3-0 desulfated heparin) as first line treatment of metastatic pancreatic cancer. Ongoing study November 2011.
190. Chemotherapy with or without preventive anticoagulation for metastatic cancer of the pancreas. Ongoing study October 2007.
191. Low molecular weight heparin in advanced non small cell lung cancer (NSCLC): a randomized open label phase III study evaluating the effect of enoxaparin (Clexane) on survival and symptom control in patients with stage IIIB and IV NSCLC undergoing a cisplatin based first line chemotherapy: the SYRINGES Trial. Ongoing study June 2008.
192. Kakkar AK, Doval DC, Fareed J, Kerr D, Maganji JM, Mueller I. Rationale and design of the GASTRANOX trial on a low-molecular-weight heparin [LMWH], enoxaparin, with chemotherapy vs. chemotherapy alone in inoperable gastric and gastro-oesophageal cancer. Annals of Oncology 2010;21:252-3. 6669117
193. A randomized phase III study of standard treatment +/- enoxaparin in small cell lung cancer. Ongoing study June 2008.
194. Long-term Prophylaxis of Venous Thromboembolism with low-molecular-weight heparin in patients with metastatic lung cancer. Ongoing study April 2017.
195. Phase III double-blind trial comparing low-molecular weight heparin (LMWH) versus placebo in patients with advanced cancer. Ongoing study December 1998.
196. A prospective randomized controlled multicenter study of the effect of dalteparin on quality of life in unresectable pancreatic cancer. Ongoing study October 2002.
197. A randomized phase II study to evaluate the effect of two different doses of enoxaparin sodium in combination with standard chemotherapy (cisplatin plus etoposide) with respect to time to tumor progression (TTP) in patients with newly diagnosed extensive stage small cell lung cancer (SCLC) without underlying venous thromboembolism. Ongoing study July 2008.
198. Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLOS One 2013;8(2):e57132.
199. Akl EA, Ramly EP, Kahale LA, Yosuico VED, Barba M, Sperati F, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD006468.pub5]
200. Akl EA, Kahale L, Neumann I, Barba M, Sperati F, Terrenato I, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD006649.pub6]
201. Akl EA, Kahale LA, Barba M, Neumann I, Labedi N, Terrenato I, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD006650.pub4]
202. Akl EA, Kahale L, Terrenato I, Neumann I, Yosuico VE, Barba M, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD006466.pub5]
203. Akl EA, Kahale LA, Ebrahim S, Alonso-Coello P, Schünemann HJ, Guyatt GH. Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers. Journal of Clinical Epidemiology 2016;76:147-54.
204. Akl EA, Meerpohl JJ, Elliott JH, Kahale LA, Schünemann HJ on behalf of the Living Systematic Review Network. Living systematic reviews: 4. living guideline recommendations. Journal of Clinical Epidemiology (in press) 2017.
205. Alifano M, Benedetti G, Trisolini R. Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer?: An urgent call for research. Chest 2004;126:601-7.
206. Alshurafa M, Briel M, Akl EA, Haines T, Moayyedi P, Gentles SJ, et al. Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLOS One 2012;7(11):e49163.
207. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116(24):5377-82.
208. Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies-systematic review and meta-analysis. Acta Oncologica 2014;53(9):1230-7.
209. Chazouilleres O, Poupon R, Gatineausaillant G, Roulot D, Barbare JC, Labadie H, et al. Beneficial effect of low molecular weight heparin (fraxiparin) on short term mortality in patients with unresectable hepatocellular carcinoma (HCC). A randomized study. Gastroenterology 1994;106(4):A874.
210. Che DH, Cao JY, Shang LH, Man YC, Yu Y. The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. European Journal of Internal Medicine 2013;24:433-9.
211. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. Journal of Clinical Oncology 2007;25:70-6.
212. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. Journal of Thrombosis Haemostasis 2008;6:601-8.
213. Cochrane Crowd. http://crowd.cochrane.org. .
214. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2009.
215. Connolly GC, Dalal M, Lin J, Khorana AA. Incidence and predictors ofvenous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer 2012;78:253-8.
216. CSR-web. http://community.cochrane.org/tools/data-management-tools/crs. .
217. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
218. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
219. Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AWS. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD008500.pub4]
220. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine 1986;315(26):1650-9.
221. Ebrahim S, Akl EA, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology 2013;66(9):1014-21.
222. Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, et al on behalf of the Living systematic review Network. Living Systematic Reviews: 1. Introduction - the Why, What, When and How. Journal of Clinical Epidemiology (in press) 2017.
223. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Seminars in Thrombosis and Hemostasis 1998;24(2):93-109.
224. Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Seminars in Thrombosis and Hemostasis 2006;32(8):803-9.
225. Schünemann H, Brozek J, Guyatt G, Oxman A. GRADE Handbook. http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. GRADE working group, Updated October 2013.
226. Guyatt GH, Ebrahim S, Alonso-Coello P, Johnston BC, Mathioudakis AG, Briel M, et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology 2017:pii: S0895-4356(16)30811-3.
227. Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice. Vox Sanguinis 2002;83(Suppl 1):383-6.
228. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
229. Hirsh J. Low molecular weight heparin. Thrombosis and Haemostasis 1993;70(1):204-7.
230. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl):141s-59s.
231. Karnofsky D. The use of nitrogen mustard in the palliative treatment of cancer. Cancer 1948;1:634-56.
232. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. Journal of Thrombosis and Haemostasis 2003;1(7):1456-63.
233. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982;5(6):649-55.
234. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
235. Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, Hahnfeld S, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial. Onkologie - DGHO meeting. October 2009; Vol. 580:Abstract. 2702943
236. Phan M, John S, Casanegra AI, Rathbun S, Mansfield A, Stoner JA, et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. Journal of Thrombosis and Thrombolysis 2014;38:241-9.
237. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
238. Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins M, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484-8.
239. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
240. Salat C, Breitruck H, Reinhardt B, Hiller E. Thromboprophylaxis with low molecular weight heparin (LMWH) and conventional low dose heparin in patients with malignant diseases. Blut 1990;61(2-3):142.
241. Simmonds ME, Salanti G, Higgins JE, McKenzie J, Elliott JE on behalf of the Living Systematic Review Network. Living Systematic Reviews: 3. Statistical methods for updating meta-analyses. Journal of Clinical Epidemiology (in press) 2017.
242. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacological Reviews 2001;53(1):93-105.
243. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010 Mar 30;340:c117.
244. Synnot A, Turner T, Elliott J with input from Elie Akl, Harriet MacLehose and the Living Systematic Review Network. Cochrane Living Systematic Reviews Interim guidance for pilots (Version 0.3, 21 April 2017). available at: http://community.cochrane.org/review-production/production-resources/living-systematic-reviews 2017.
245. Thodiyil P, Kakkar AK. Can low-molecular-weight heparins improve outcomes in patients with cancer?. Cancer Treatment Reviews 2002;28:151-5.
246. Wallace BC, Noel-Storr A, Marshall IJ, Cohen AM, Smalheiser NR, Thomas J. Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach. Journal of the American Medical Informatics Association 2017;0(0):1-4. [DOI: 10.1093/jamia/ocx053]
247. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009;373(9663):567-74.
248. Zhang J1, Zhang YL, Ma KX, Qu JM. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax 2013;68(5):442-450.
249. Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006652]
250. Akl EA, Gunukula S, Barba M, Yosuico VED, van Doormaal FF, Kuipers S, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD006652.pub2]
251. Akl EA, Gunukula S, Barba M, Yosuico VED, van Doormaal FF, Kuipers S, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD006652.pub3]
252. Akl EA, Kahale LA, Ballout RA, Barba M, Yosuico VE, van Doormaal FF, et al. Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD006652.pub4]